Passa al contenuto
Merck
Tutte le immagini(2)

Key Documents

917796

Sigma-Aldrich

NanoFabTx PEG-PLGA drug formulation screening kit

for synthesis of PEGylated nanoparticles

Sinonimo/i:

NanoFabTx reagent kit, PEG-PLGA nanoparticles

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali


About This Item

Codice UNSPSC:
12161503
NACRES:
NA.23

Descrizione

Drug loading screening kit, for synthesis of PEGylated PLGA nanoparticles
Kit components :
PEGPLGA-50L(912808-500mg)
PEGPLGA-75L(913049-500mg)
PEGPLGA-50H (915955-500mg)
PEGPLGA-75H (915718-500mg)
Stabilizer-Nano (907766-5g)

Livello qualitativo

applicazioni

advanced drug delivery

Temperatura di conservazione

2-8°C

Descrizione generale

NanoFabTx PEG-PLGA drug loading screening kit is a ready-to-use nanoformulation kit for the synthesis of PEGylated PLGA nanoparticles 50 nm to 350 nm in size. This kit provides properly selected PEGylated PLGAs, stabilizer, and formulation protocols for synthesis by nanoprecipitation and microfluidic methods. Four different PEGylated PLGAs are included in this kit, allowing rapid screening of optimal materials for enhancing drug loading. Protocols for two different particle synthesis methods are included.
  • A Nanoprecipitation protocol to prepare drug-encapsulated nanoparticles in standard laboratory glassware.
  • A Microfluidics protocol using commercial platforms or syringe pumps.
The microfluidics protocol uses NanoFabTx device kits (911593), which provide all the microfluidics chips, fittings, and tubing required to get started with microfluidics-based synthesis (compatible microfluidics system or syringe pump required).

Applicazioni

NanoFabTx nanoformulation reagent kits enable users to encapsulate a wide variety of therapeutic drug molecules in PEGylated PLGA nanocarriers for targeted or sustained drug delivery without the need for lengthy trial-and-error optimization. PEGylated PLGAs are well suited towards applications involving sustained release because PEGylation has been shown to improve the circulation half-life of polymeric nanocarriers by altering the solubility and shielding the nanocarrier from enzymes and antibodies that may induce degradation, secretion, and clearance. Because poly(lactic-co-glycolic acid) (PLGA) is a biocompatible and biodegradable polymer approved by the FDA for biomedical and pharmaceutical applications, PLGA-based nanoparticles synthesized with the NanoFabTx kits are suitable for biomedical research applications such as oncology, immuno-oncology, gene delivery, and vaccine delivery.

Caratteristiche e vantaggi

  • Requires minimal laboratory setup
  • Optimized protocols with step-by-step instructions for either nanoprecipitation or microfluidics-based synthesis
  • Yields specifically sized, low polydispersity biodegradable, PEGylated PLGA nanoparticles from 50 nm to 350 nm in size
  • Maximizes the encapsulation of hydrophobic drugs
  • Four different PEGylated PLGAs are included

Note legali

NANOFABTX is a trademark of Sigma-Aldrich Co. LLC

Codice della classe di stoccaggio

10 - Combustible liquids


Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

Ci dispiace, ma al momento non ci sono COA disponibili online per questo prodotto.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Susanne Schöttler et al.
Nature nanotechnology, 11(4), 372-377 (2016-02-16)
The current gold standard to reduce non-specific cellular uptake of drug delivery vehicles is by covalent attachment of poly(ethylene glycol) (PEG). It is thought that PEG can reduce protein adsorption and thereby confer a stealth effect. Here, we show that
Hassan A Almoustafa et al.
International journal of pharmaceutics, 533(1), 275-284 (2017-09-26)
Nanoprecipitation is a simple and increasingly trending method for nanoparticles preparation. The self-assembly feature of poly (ethylene glycol)-poly (lactide-co-glycolic acid) (PEG-PLGA) amphiphilic copolymer into a nanoparticle and its versatile structure makes nanoprecipitation one of the best methods for its preparation.
Y Li et al.
Journal of controlled release : official journal of the Controlled Release Society, 71(2), 203-211 (2001-03-29)
The aim of the present work was to assess the merits of PEGylated poly(lactic-co-glycolic acid) (PEG-PLGA) nanoparticles as protein and peptide drugs (PPD) carriers. PEG-PLGA copolymer, which could be used to prepare the stealth nanoparticles or long-circulating nanoparticles, was synthesized
L Martin-Banderas et al.
Mini reviews in medicinal chemistry, 13(1), 58-69 (2012-09-15)
This article presents the potential of PLGA nanoparticles for the oral administration of drugs. Different strategies are used to improve oral absorption of these nanoparticles. These strategies are based on modification of nanoparticle surface properties. They can be achieved either
Which polymers can make nanoparticulate drug carriers long-circulating?
Torchilin V P, et al.
Advanced Drug Delivery Reviews, 16, 141-155 (1995)

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.